Although observational studies suggest that people taking these medications are less likely to develop Alzheimer’s, the idea hasn’t been tested in trials yet. The Alzheimer’s Association is funding a $100 million trial attempting to combine a GLP-1 drug with intensive lifestyle interventions to see if it could prevent the disease.